Navigation Links
Meda to License Elidel to Valeant Pharmaceuticals

MISSISSAUGA, Ontario, April 7, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced today that its subsidiary, Valeant International (Barbados) SRL (VIB), received a commitment in principle to license Elidel (pimecrolimus 1% cream) from Meda in the U.S., Canada and Mexico.  Terms of the license will be disclosed after the parties have executed a definitive agreement.  Earlier today Meda announced that it reached a definitive agreement to acquire global rights to Elidel from Novartis.  Elidel is a patent protected specialty focused product for the treatment of atopic dermatitis (AD).  Meda's acquisition of Elidel is subject to certain customary closing conditions, including expiration or early termination of the waiting period under the Hart-Scott-Rodino Act.  

"We are pleased to add this strong worldwide brand to our growing dermatology product portfolio," state J. Michael Pearson, chairman and chief executive officer.  "Elidel not only strengthens our presence with dermatologists in our key markets, but this product should be a complementary addition to our currently marketed products."  

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at

Caution Regarding Forward-Looking Information

To the extent any statements made in this document contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information as defined under applicable Canadian securities legislation (collectively, "forward-looking statements").

These forward-looking statements relate to, among other things, the acquisition by Meda of Elidel, the license of Elidel by Meda to Valeant and, the impact of Elidel on Valeant's dermatology portfolio.  Forward-looking statements can generally be identified by the use of words such as "believe", "anticipate", "expect", "estimate", "intend", "continue", "plan", "project", "will", "may", "should", "could", "would", "target", "potential" and other similar expressions.  In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.  Actual results may differ materially from those expressed or implied in such statements.  Important factors that could cause actual results to differ materially from these expectations include, among other things, the impact of Elidel on Valeant's dermatology portfolio and the impact of the acquisitions on Valeant's results, and the risk factors as detailed from time to time in Valeant's reports filed with the Securities and Exchange Commission ("SEC") and the Canadian Securities Administrators ("CSA").  

Contact Information:
Laurie W. Little


SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Extends Review Timeline for Ustekinumab Biologic License Application Three Months
2. Interleukin Genetics Licenses its PST(R) Genetic Test to OralDNA Labs
3. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
4. BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
5. ReceptorBio Announces Diabetes License Agreement With Telik
6. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
7. LGE Execs Teams with Texas Tech to License Advancements in Agriculture, Health and Life Sciences
8. CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group
9. Nomad Bioscience Announces Broad License Agreement
10. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
11. Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy
Post Your Comments:
(Date:11/24/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. ... will provide a corporate overview. th Annual Oppenheimer ... p.m. ET/10:00 a.m. PT . Jim Mazzola , vice ... overview. --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential micronutrient ... to proteins, copper is also toxic to cells. With a $1.3 million award ... will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa (P. ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ - ... the request of IIROC on behalf of the Toronto ... this news release there are no corporate developments that ... price. --> --> ... --> . --> Aeterna Zentaris ...
(Date:11/24/2015)... 2015 --> ... "Oligonucleotide Synthesis Market by Product & Services (Primer, Probe, ... DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) ... market is expected to reach USD 1,918.6 Million by ... CAGR of 10.1% during the forecast period. ...
Breaking Biology Technology:
(Date:10/29/2015)... 29, 2015  The J. Craig Venter Institute (JCVI) ... Synthesis and Biosecurity: Lessons Learned and Options for the ... and Human Services guidance for synthetic biology providers has ... --> --> Synthetic biology ... potential to pose unique biosecurity threats. It now is ...
(Date:10/29/2015)... 2015 Today, LifeBEAM , a ... 2XU, a global leader in technical performance sports ... with advanced bio-sensing technology. The hat will allow ... key biometrics to improve overall training performance. As ... will bring together the most advanced technology, extensive ...
(Date:10/26/2015)... and LAS VEGAS , Oct. ... Labs , an innovator in modern authentication and a ... announced the launch of its latest version of the ... enabling organizations to use standards-based authentication that supports existing ... S3 Authentication Suite is ideal for organizations deploying customer-facing ...
Breaking Biology News(10 mins):